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Introduction
Ovarian cancer is the fifth most common cancer in the 
female population in the United States, accounting for 
approximately 5% of all cancers diagnosed among women.1-
4 The conventional course of therapy is maximal surgical 
debulking of the tumor mass followed by a combination of 
taxane and platinum-based chemotherapy.5 Despite 70% of 
patients initially responding well to treatment, the emer-
gence of drug resistance and side effects has rendered a 
wide variety of the currently available chemotherapeutic 
agents ineffective,6 and the 5-year survival rate remains less 
than 40%.1-3,5,7,8 Hence, there is a compelling need to 
explore novel therapeutic interventions for this disease.
The present studies were aimed at identification of alter-
native therapeutic approaches to enhance the efficacy of 
current chemotherapeutic regimes using nontoxic nutraceu-
ticals that have health benefits beyond their normal nutri-
tional properties.9 Bitter melon (Momordica charantia), 
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Abstract
Objective. Acquired chemoresistance is a major obstacle in the clinical management of ovarian cancer. Therefore, searching 
for alternative therapeutic modalities is urgently needed. Bitter melon (Momordica charantia) is a traditional dietary fruit, 
but its extract also shows potential medicinal values in human diabetes and cancers. Here, we sought to investigate 
the extract of bitter melon (BME) in antitumorigenic and cisplatin-induced cytotoxicity in ovarian cancer cells. Methods. 
Three varieties of bitter melon were used to prepare the BME. Ovarian cancer cell lines, human immortalized epithelial 
ovarian cells (HOSEs), and nude mice were used to evaluate the cell cytotoxicity, cisplatin resistance, and tumor inhibitory 
effect of BME. The molecular mechanism of BME was examined by Western blotting. Results. Cotreatment with BME 
and cisplatin markedly attenuated tumor growth in vitro and in vivo in a mouse xenograft model, whereas there was no 
observable toxicity in HOSEs or in nude mice in vivo. Interestingly, the antitumorigenic effects of BME varied with different 
varieties of bitter melon, suggesting that the amount of antitumorigenic substances may vary. Studies of the molecular 
mechanism demonstrated that BME activates AMP-activated protein kinase (AMPK) in an AMP-independent but CaMKK 
(Ca2+/calmodulin-dependent protein kinase)-dependent manner, exerting anticancer effects through activation of AMPK 
and suppression of the mTOR/p70S6K and/or the AKT/ERK/FOXM1 (Forkhead Box M1) signaling cascade. Conclusion. BME 
functions as a natural AMPK activator in the inhibition of ovarian cancer cell growth and might be useful as a supplement 
to improve the efficacy of cisplatin-based chemotherapy in ovarian cancer.
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which is a popular herb in ancient folk medicines in China, 
India, Southeast Asia, and Central America, has received 
much global recognition not only because of its remarkable 
hypoglycemic effects, but also because of its recently rec-
ognized anticancer effects. The findings that bitter melon 
exhibits anticancer properties is reminiscent of metformin, a 
derivative of a natural plant product, originally developed as 
an insulin-sensitizing and antihyperglycemic drug used in 
the treatment of type II diabetes mellitus.10 Recently, it has 
been suggested that the anticancer effects of metformin11,12 
might be a result of its capability to stimulate AMP-activated 
protein kinase (AMPK).13 AMPK is a cellular energy sensor 
that plays an important role in the maintenance of energy 
homeostasis in response to external stresses.14,15 Recent 
studies have suggested that AMPK reprograms cancer cell 
metabolism and inhibits cell proliferation in various human 
cancers.16,17 Our previous investigations have demonstrated 
that growth of cervical cancer cells is significantly sup-
pressed by a number of pharmacological activators of 
AMPK, such as metformin, AICAR, and A23187, by reduc-
ing the Wnt/β-catenin18 and AKT/FOXO3a/Forkhead Box 
M1 (FOXM1)19 signaling cascades. However, because of 
the toxic side effects of conventional AMPK activators such 
as metformin, which can cause lactic acidosis and gastroin-
testinal side effects,20,21 the use of nontoxic, natural AMPK 
activators may be preferable to combat the development of 
ovarian cancer and chemoresistance.
Recent studies have suggested that extract of bitter 
melon (BME) contains triterpenoids and possesses the abil-
ity to activate AMPK and induce GLUT4 translocation9,22; 
however, its antitumor effects and the underlying molecular 
mechanisms are not totally clear. BME has potent antitumor 
activity against different cancer cells, probably because of 
the presence of some of its active components, including 
triterpenoids such as cucurbitacin B (cucB) and kuguacin J. 
Triterpenoids from a wide range of botanicals have already 
been confirmed to possess antiproliferative23-25 and anti-
invasive26,27 features. More than 50 triterpenoids indeed 
have been extracted from bitter melon; however, their bio-
logical functions have yet to be investigated in detail. 
Recently, it had been reported that cucB, a triterpenoid from 
Cucurbitaceae vegetables, existed in the seeds of bitter 
melon as well and had induced cell cycle arrest and apopto-
sis in human colon adenocarcinoma cancer cells.25 Another 
triterpenoid, kuguacin J, which accounts for only around 
1.6% of bitter melon leaf extract, had been shown to signifi-
cantly inhibit cancer and/or carcinogenesis by causing cell 
cycle arrest at the G1 phase and inducing apoptosis in pre-
initiated or initiated tumor cells. In more advanced tumors, 
kuguacin J not only had the ability to sensitize chemoresis-
tant cancer cells to anticancer drug–induced cell death, but 
also to successfully block tumor progression and metasta-
sis, implying that natural compounds from BME might be 
useful in the development of chemopreventive as well as 
chemotherapeutic agents.
In this study, we examined the anticancer effects of BME 
and compared the tumor-suppressive properties of different 
varieties of bitter melon. Studies of the molecular mechanism 
revealed that BME acts as a natural AMPK activator, increas-
ing AMPK through Ca2+/calmodulin-dependent protein 
kinase-β (CaMKKβ) signaling in an AMP-independent 
manner, which in turn represses both mTOR/p70S6K and 
AKT/ERK/FOXM1 signals. It is important to note that based 
on the nontoxic nature of BME, we explored the possibility 
of using BME as a potential supplement to improve the effi-
cacy of cisplatin-based chemotherapy in ovarian cancer.
Materials and Methods
Cell Culture, BME, and Drugs
Ovarian cancer cell lines A2780cp, A2780s, C13*, OV2008 
(provided by Professor B. K. Tsang, Department of Obstetrics 
and Gynecology, University of Ottawa, Canada; authentica-
tion of cell lines carried out by in-house STR DNA profiling 
analysis), SKOV3, OVCA433, ES2 (American Type Culture 
Collection, Rockville, MD), and 2 human immortalized epi-
thelial ovarian cells (HOSEs), HOSE17-1 and HOSE 96-9-
18 (provided by Professor G. S. W. Tsao, Department of 
Anatomy, The University of Hong Kong), were used in this 
study. Cells were maintained in Dulbecco’s Modified Eagle’s 
Medium (Invitrogen Life Technologies, Carlsbad, CA) sup-
plemented with 10% (volume/volume [v/v]) fetal bovine 
serum (Invitrogen, Gibco, Gaithersburg, MD, USA ) and 100 
U/mL penicillin/streptomycin (Invitrogen Life Technologies, 
Carlsbad, CA) in an incubator at 37°C with humidified 
atmosphere of 5% CO
2
 and 95% air. Three varieties of 
 young bitter melon (not yet ripe) such as Thailand, Chinese, 
and Taiwanese were purchased from the supermarket 
(Supplementary Figure S1, available at http://ict.sagepub.
com/supplemental). After being washed and deseeded, bitter 
melon extract (BME) of each variety was extracted according 
to the method described in previous publications.28,29 Briefly, 
BME was extracted by a household blender and centrifuged 
at 500g at 4°C for half an hour (Supplementary Figure S1). 
The supernatant was filtered using a 0.22 µm syringe filter 
and stored in aliquots at −80°C for future use. As needed, 
0.25% to 10% (v/v in medium) of pure BME was used for in 
vitro and in vivo studies. The BME samples were stored at the 
Department of Obstetrics and Gynecology, University of 
Hong Kong. AMPK activators AICAR, A23187, and metfor-
min and the CaMKKβ inhibitor STO-609 were obtained 
from Tocris Bioscience (Bristol, UK).
HEK-293 Cells Expressing Tetracycline-Inducible 
AMPK-γ2 (Wild Type or Mutant) and RNAi-
Mediated AMPKα1 Knockdown
DNA encoding full-length human AMPK-γ2 was amplified 
with primers designed to encode a 5′-BamHI site and a 
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C-terminal FLAG tag followed by an XhoI site. The result-
ing polymerase chain reaction (PCR) product was cloned 
into the pcDNA5/FRT (Flp recombinase target)/TO plasmid 
(Invitrogen) to create the plasmid pcDND5/FRT/TO/γ2. The 
R531G mutation was created in this plasmid using the 
QuikChange Site-Directed Mutagenesis system (Stratagene). 
T-Rex HEK293 cells containing a single FRT site (Invitrogen) 
were transfected with Fugene6 (Promega, Madison, WI, 
USA ) using the plasmids POG44 encoding Flp recombinase 
(Invitrogen) and pcDND5/FRT/TO/γ2 at a ratio of 9:1. After 
48 hours, the cells were detached using trysin and replated in 
medium containing hygromycin B (200 µg/mL) and blastici-
din (15 µg/mL). The medium was replaced every 3 days 
until cell foci could be identified, and individual foci were 
then selected and expanded. The expression of FLAG-
tagged AMPK-γ2 was checked using Western blotting with 
anti-FLAG antibodies (Sigma-Aldrich, St Louis, MO). 
Expression of AMPK-γ2 (wild-type, AMP-sensitive [WT] 
or AMP/ADP-insensitive R531G mutant [RG]) was induced 
with tetracycline (1 µg/mL) for 48 hours. To knockdown 
human AMPKα1, the TriFECTa RNAi Kit, which contains 3 
siRNAs specifically targeting human AMPKα1, was pur-
chased from IDT (Integrated DNA Technologies, Inc, Iowa). 
Cell transfection was carried out using LipofectAMINETM 
2000 (Invitrogen) according to the manufacturer’s instruc-
tions. The universal negative control siRNA (IDT) was used 
as scrambled control, and Western blotting was used to 
verify the expression of AMPKα1.
RNA Extraction and Real-Time Quantitative 
Reverse Transcription PCR (qPCR)
Total RNA was extracted using TRIzol reagent (Invitrogen) 
according to the manufacturer’s instructions. Complementary 
DNA (cDNA) was synthesized using a reverse transcription 
reagent kit (Applied Biosystems, Foster City). The expression 
level of FOXM1 was evaluated by qPCR in an ABI PRISM 
7500 system (Applied Biosystems) using Taqman gene 
expression assays: human FOXM1 (Assay ID: Hs00153543_
m1). Human 18S rRNA (Assay ID: Hs99999901_m1) was 
used as an internal control.
Western Blot Analysis
Proteins in cell lysates were separated by 10% SDS-PAGE 
and transferred to polyvinylidene-difluoride membranes. 
The membranes were blotted with 5% skimmed milk and 
subsequently probed overnight at 4°C with primary antibod-
ies specific for anti-p-AMPKα, anti-AMPKα1, anti-AMPKα, 
anti-p-AKT, anti-AKT, anti-p-p70S6K, anti-p-mTOR, anti-
mTOR (Cell Signaling, Beverly, MA), anti-p-ERK, anti-ERK, 
anti-FOXM1 (Santa Cruz Biotechnology, Inc, Santa Cruz, CA), 
and anti-β-actin (Sigma-Aldrich, St Louis, MO) and then incu-
bated with horseradish peroxidase conjugated goat antirabbit 
or antimouse secondary antibody (Amersham, Uppsala, 
Sweden). Immunodetection was performed with enhanced 
chemiluminescence reagent solution (Amersham ECL) and 
visualized by medical X-ray film.
Cell Proliferation and Focus Formation Assays
An XTT cell proliferation kit (Roche, Basel, Switzerland) 
was used to measure cell viability according to the manu-
facturer’s protocol. Three independent experiments were 
performed in triplicate. For focus formation assay, approxi-
mately 1000 to 3000 cells were cultured in each well of a 
6-well plate and treated with different drugs. After incuba-
tion at 37°C in an incubator for 2 weeks, colonies were 
stained with crystal violet and counted.
Wound Healing and Matrigel Cell Migration and 
Invasion Assays
For wound healing assays, an equal amount of cells was 
grown as a monolayer to 90% confluence in a 6-well plate. 
The cells were pretreated with 10 µg/mL mitomycin C for 2 
hours, and a wound was then scratched with a sterile 200 µL 
pipette tip in each well. After washing each well with phos-
phate buffered saline (PBS), cells were treated with drugs 
and incubated at 37°C in a humidified, 5% CO
2
 atmosphere. 
The width of each wound was monitored at specific time 
intervals, with the relative velocity of cell migration being 
calculated by dividing the width over time.
For Matrigel cell migration and invasion assays 
(Millipore), 300 µL of cell suspension containing 1 × 106 
cells/mL in serum-free medium was added to each insert. 
The medium (500 µL) containing 10% fetal bovine serum 
was added to the lower chamber as a chemoattractant. After 
1 to 2 days, the migrated cells were stained and counted by 
microscopy.
Fluorescence-Activated Cell Sorting
Cell cycle analysis was carried out to elucidate cell cycle 
arrest and apoptosis induced by AMPK activator or BME 
by means of propidium iodide staining and flow cytometry. 
Ovarian cancer cells were initially suspended in serum-free 
medium and subsequently seeded into 6-well plates at a 
density of 0.5 × 106 viable cells per well. The cells were 
incubated overnight at 37°C in an incubator with a humidi-
fied atmosphere of 5% CO
2
 and 95% air. The full medium 
together with either AMPK activator or BME was applied 
to the cells on the next day, and the plates were incubated 
overnight as before. Cell pellets were collected by centrifu-
gation at 1500g for 5 minutes and fixed in cold 70% etha-
nol. The cells were analyzed by a flow cytometer (BD 
Biosciences), and the number of cells in each phase of the 
cell cycle was quantified by Modfit software.
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In Vivo Tumorigenicity Assay
To study the in vivo consequences of BME on tumor devel-
opment, 1 × 106 ovarian cancer cells ES2 were implanted 
subcutaneously into the right flank of 5-week old BALB/
cAnN-nu female nude mice in groups of 5. Intraperitoneal 
administration of BME was, therefore, started to pretreat 
the mice for 2 days, and afterward cisplatin treatment was 
initiated every other day for a total of 6 injections. Treatment 
with BME was continued during cisplatin treatment. For 
the control group, PBS was injected intraperitoneally at the 
same times. The sizes of tumors were determined at the 
time of each injection utilizing a digital slide caliper and 
were evaluated using the following formula: Volume = 
[(Width + Length) ÷ 2]3 × π/6. All experimental procedures 
described in this report were submitted to and approved by 
The Committee on the Use of Live Animals in Teaching and 
Research (CULATR number: 2560-11) of the University of 
Hong Kong.
Data Analysis
The Student t test was used to analyze parametric data, 
whereas the Mann-Whitney test was used for nonparamet-
ric data. A P value ≤.05 was considered significant.
Results
BME Specifically Inhibits Ovarian Cancer Cell 
Growth
Given that a known AMPK activator such as metformin 
mediated growth inhibitory effects on human ovarian can-
cer cells (Supplementary Figure S2A, available at http://ict.
sagepub.com/supplemental), we examined whether a poten-
tial natural AMPK activator, BME, could mediate the same 
effect. Several human ovarian cancer cell lines were treated 
with different dilutions (0%, 0.25%, 0.5, and 1%, v/v) of 
Chinese BME, so that the majority of the cells could main-
tain appropriate viability and their respective proliferation 
rates could be measured by XTT cell proliferation assay for 
5 days. After BME treatment, growth of A2780cp (P ≤ .05), 
A2780s (P ≤ .05), C13* (P < .05), and OV2008 (P ≤ .05) 
cells was significantly inhibited from 20% to 87% com-
pared with controls, but there was no significant effect on 
the proliferation of immortalized human ovarian surface 
epithelial (HOSE 17-1) cells (Figure 1A). In addition, focus 
formation assays showed that the number of colonies was 
markedly reduced by 30% and 70% in A2780cp and C13* 
cells, respectively, whereas there was no effect using 
HOSE17-1 cells (Figure 1B). These results show that BME 
functions similarly to a known pharmacological activator of 
AMPK in attenuating cell growth of human ovarian cancer 
cells while having no cytotoxic effects on normal ovarian 
epithelial cells.
BME Induces Cell Growth Arrest and Apoptosis 
in Ovarian Cancer Cells
Because long-term inhibitory effects of BME on cell viabil-
ity of human ovarian carcinoma cells were observed, we 
examined whether it modulates cell cycle progression and 
induces apoptotic cell death in a manner similar to known 
pharmacological activators of AMPK (Supplementary 
Figure S2B). Similar to metformin, treatment for 24 hours 
with 10% (v/v) Chinese BME of the ovarian cancer cell line 
A2780cp yielded a small but significant increase in cells 
arrested in the G1 phase and a decrease in cells in the S 
phase compared with untreated controls (Figure 1C). On the 
other hand, apoptotic cell death of A2780cp cells after BME 
treatment was also elevated, as indicated by the 40% 
increase in the sub-G1 cell content compared with untreated 
controls (Figure 1C). Furthermore, Western blot analysis 
demonstrated that treatment with 5% or 10% (v/v) Chinese 
BME increased cleavage of PARP and caspase 3, both 
markers of apoptosis, in both C13* and OV2008 cells 
(Figure 1D). Additionally, 5% or 10% (v/v) Chinese BME 
enhanced the phosphorylation of SAPK/JNK, c-Jun, p38, 
MAPKAPK-2, and HSP27 in C13* and OV2008 cells, sug-
gesting that BME induced apoptosis in human ovarian can-
cer cells via intrinsic apoptotic mechanisms.
BME Inhibits Migration and Invasion of Ovarian 
Cancer Cells
Previous studies have reported that activation of AMPK by 
AICAR or metformin not only inhibits cell proliferation but 
also retards cell migration,30,31 which might further enhance 
its capacity for tumor suppression. Thus, it was of interest 
to determine whether BME impaired migration and inva-
sion of human ovarian cancer cells. In this study, the ovar-
ian cancer cell line SKOV3, a higher migratory cell line, 
was subjected to BME treatment. Wound healing assays 
showed that the wound closure rate of SKOV3 cells was 
significantly slowed by BME in a concentration-dependent 
manner, yielding 40% to 50% reduction of cell migration on 
treatment with 5% and 10% (v/v) Chinese BME (Figure 2A). 
In addition, transwell cell migration assays showed that 
around 50% reduction in cell migration of SKOV3 cells was 
caused by 5% or 10% (v/v) Chinese BME treatment, com-
pared with untreated controls (Figure 2B). Moreover, tran-
swell invasion assays showed that the number of cells that 
invaded through the matrigel was reduced by ~60% in 
SKOV3 cells treated with 10% BME (Figure 2C).
BME Inhibits Tumor Growth of Ovarian Cancer 
Cells In Vivo
We next determined whether BME could impair tumor 
growth in a mouse xenograft tumor model. An interesting 
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finding from a recent study was that Thai bitter ground 
fruits contained monofunctional phase II enzyme inducers 
that stimulated phase II enzymes and inhibited mono-oxy-
genase in rat liver, whereas a Chinese variety only contained 
bioactive compounds capable of affecting mono-oxygenase 
in rats.32 Given the diverse effects exerted by different vari-
eties of bitter melon, different varieties of BME may also 
have differing efficacies in inhibiting ovarian tumor growth. 
In this study, a highly metastatic ovarian cancer cell line, 
ES2, was inoculated subcutaneously into female nude mice, 
and when a palpable tumor was formed, 10% (v/v) BME 
from bitter melon of Taiwanese or Chinese varieties was 
administered intraperitoneally every 2 days, with a total of 6 
injections. As shown in Figure 3A, Taiwanese and Chinese 
BME significantly suppressed tumor growth by 1.4- to 
2-fold, respectively, compared with the PBS-treated con-
trols. The tumor weights displayed 40% to 70% reductions 
on day 12 in the Taiwanese and Chinese BME-treated groups 
(Figures 3B and 3C). These findings are consistent with our 
in vitro tumor growth results and further support our notion 
that different varieties of BME have strong suppressive 
capacity in ovarian cancer tumor growth in vivo.
Different Varieties of Bitter Melon Have 
Different Capacities to Sensitize Ovarian Cancer 
Cells to Cisplatin/Taxol-Induced Cell Cytotoxicity
Despite the efficacy of platinum-based drugs such as cispla-
tin in killing cancer cells, development of cellular resistance 
to these drugs causes obstacles in the clinical management 
of the disease.33,34 Recent evidence has indicated that phar-
macological activators of AMPK such as metformin could 
enhance cisplatin-induced cell cytotoxicity.35 Considering 
the speculation that BME acts as a potential natural AMPK 
activator that inhibits ovarian cancer cell growth, it was of 
interest to explore whether BME could enhance cisplatin-
mediated cell cytotoxicity. In this study, two cisplatin-resis-
tant cell lines, A2780cp and C13*, were treated with 
Chinese BME and cisplatin. Treatment with either 0.5% to 
Figure 1. BME impairs cell growth and induces cell cycle arrest and apoptosis in ovarian cancer cells. (A) Concentration-dependent 
inhibition of cell proliferation in A2780cp (P ≤ .05), A2780s (P ≤ .05), C13* (P < .05), and OV2008 (P ≤ .05) cells treated with 
Chinese BME for 5 days was seen using XTT assays, whereas no inhibition was observed in HOSE cells. (B) Focus formation assay 
demonstrating a significant reduction of the number of colonies formed in A2780cp and C13* cells treated with 0.25% and 0.5% 
(volume/volume [v/v]) Chinese BME, with no apparent inhibition of colony formation in HOSE cells. (C) Upper: A2780cp cells 
were rapidly treated with 10% (v/v) Chinese BME for 24 hours, and the extent of cell cycle arrest and apoptosis was estimated by 
propidium iodide–based flow cytometry. Lower: C13* and OV2008 cells were treated with 5% and 10% (v/v) Chinese BME for 24 
hours, and Western blot analysis was performed to examine the effects on cleavage of caspase 3 and PARP, and phosphorylation of 
SAPK/JNK, c-Jun, p38, MAPKAPK-2, and HSP27. Representative cropped blots are presented.
Abbreviations: BME, extract of bitter melon; HOSE, human immortalized epithelial ovarian cells.
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1% (v/v) BME was equivalent to a high dose of cisplatin (3 
µg/mL) in suppressing the cell proliferation of A2780cp and 
C13* cells, whereas cotreatment with BME and cisplatin 
further enhanced cisplatin-mediated cell cytotoxicity by 
~2-fold (Figure 4A). Next, the effect of BMEs from 2 other 
varieties—that is, Taiwanese and Thai—on chemoresistance 
Figure 2. Bitter melon extract (BME) inhibits ovarian cancer cell migration and invasion. (A) Wound healing assays demonstrating 
that there was a marked retardation in wound closure rate of SKOV3 cells treated with 5% and 10% (v/v) Chinese BME compared 
with untreated controls over a time course of 12 hours (*P ≤ .001). The width of the wound is indicated by arrows in the 
photographs; 3 independent experiments were performed. (B) Transwell migration assay showed that SKOV3 cells with Chinese BME 
treatment (5% and 10%) exhibited a significant reduction in the number of cells penetrating through the membrane as compared with 
untreated controls (*P ≤ .001). (C) SKOV3 cells treated with Chinese BME (10%) showed less invaded cells through the matrigel as 
compared with the control (*P = .0006). The numbers of migrated or invaded cells in 3 randomly chosen fields were counted for 3 
independent experiments, and the normalized numerical data were presented in bar charts with error bars.
Figure 3. Bitter melon extract (BME) from different varieties of bitter melon displays significant antitumor effects in an ES2 xenograft 
mouse tumor model. (A) ES2 cells were subcutaneously injected into the right flank of female nude mice. On the seventh day after 
tumor cell injection, treatments with 10% (v/v) Taiwanese (TW) and Chinese BME (100 µL) were initiated and carried on every 
other day, with a total of 6 injections. Treatment with 10% (v/v) TW (*P = .01) and Chinese BME (**P = .0007) in PBS resulted in a 
slower rate of tumor growth as compared with PBS-treated controls. The tumor volume of each group was measured for 12 days 
and expressed as the mean ± SEM from 5 mice. (B) Chinese and Taiwanese BME markedly diminished (28%-71%) tumor weight, when 
compared with controls, on day 12. (C) Photographs illustrate that excised tumors from nude mice subcutaneously injected with 
ovarian cancer cell lines ES2 exhibited tumor stasis after BME injection, as evidenced by the smaller tumor sizes.
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was examined. Treated with a lower concentration of cispl-
atin (1.5 µg/mL), there was only a slight inhibition of cell 
growth in both A2780cp and C13* (Figure 4B). However, 
the cell growth of both cell lines was reduced by 18% to 
30% on treatment with 1% (v/v) Taiwanese or Thai BME 
(Figure 4B). Cotreatment with either Taiwanese or Thai 
BME and cisplatin (1.5 µg/mL) further enhanced inhibition 
of cell growth by 40% to 50% compared with cisplatin 
alone, in both cell lines (Figure 4B). Interestingly, cotreat-
ment with 1% (v/v) Chinese BME and taxol (1 ng/mL) also 
significantly inhibited A2780cp cell growth by 50%, com-
pared with either treatment alone (Figure 4C).
To further investigate whether BME enhanced cisplatin-
induced cell cytotoxicity against ovarian cancer cells in an 
in vivo tumor model, ES2 tumor-bearing nude mice were 
intraperitoneally injected with Chinese BME (2.5% and 
10%, v/v) and cisplatin (3 µg/kg) every alternate day for 12 
days. Consistent with the in vitro data, BME further reduced, 
in a dose-dependent manner, cisplatin-mediated tumor 
growth retardation by 25% to 50% compared with cisplatin 
alone (Figure 4D).
BME Activates AMPK and Suppresses mTOR in 
an AMP-Independent Manner via the CaMKKβ 
Pathway
Many AMPK activators are secondary metabolites of plants 
that act as inhibitors of mitochondrial function, in which 
case AMPK activation is induced by increased cellular 
ratios of AMP to ATP or ADP to ATP and is accompanied by 
decreases in cellular oxygen uptake.36 We studied the mech-
anism of activation of AMPK by BME using isogenic 
HEK293 cell lines expressing AMPK complexes contain-
ing either WT cells or RG cells. These were similar to cell 
lines constructed previously,36 except that expression of the 
Figure 4. BME synergistically enhanced cisplatin-mediated cell cytotoxicity of chemoresistant ovarian cancer cells. (A) XTT cell 
proliferation assay demonstrated that the growth rates of A2780cp and C13* cells were significantly reduced after treatment with 
BME. The growth inhibitory effect was more obvious when cells were treated with BME plus cisplatin, rather than cisplatin or BME 
alone. (B) Different varieties of bitter melon—Taiwanese (TW) and Thailand (Thai)—when administered with cisplatin (1.5 µg/mL), 
exerted similar synergistic growth inhibitory effects on the viability of the chemoresistant ovarian cancer cell lines, A2780cp and C13*. 
(C) BME could synergistically enhance cell cytotoxicity of taxol (1 ng/mL) in chemoresistant ovarian cancer cells. (D) BME displayed 
antitumor growth of an ES2 mouse xenograft tumor model. ES2 cells were inoculated subcutaneously in the right flank of female nude 
mice. On the seventh day of tumor cell injection, BME and cisplatin (3 mg/kg body weight) were intraperitoneally injected into the 
nude mice on alternate days for a total of 6 injections each. BME administration not only significantly reduced tumor growth but also 
enhanced cisplatin-induced cytotoxicity, as evidenced by a smaller tumor size.
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AMPK-γ2 was tetracycline inducible because we have 
found that cells stably expressing the RG mutant are unsta-
ble and lose the mutant protein on repeated passaging 
(Supplementary Figure S3, available at http://ict.sagepub.
com/supplemental). BME was similar to A23187 and 
increased Thr172 phosphorylation on AMPK in both WT 
and RG cells in a concentration- and time-dependent man-
ner (Figures 5A and 5B), indicating that BME activates 
AMPK via an AMP-independent mechanism rather than by 
increasing cellular AMP or ADP (Supplementary Figure S3). 
AMPK can also be phosphorylated and activated in an Ca2+-
dependent and AMP-independent manner by CaMKKβ,37 so 
we examined whether CaMKKβ is involved in BME-
mediated AMPK activation. Consistent with this, the cell-
permeable CaMKK inhibitor STO-609 completely blocked 
Thr172 phosphorylation in response to the calcium ionophore 
A23187 (positive control) as well as BME in both WT and RG 
cells (Figure 5C). On the other hand, it is known that LKB1/
AMPK signaling is one of the most well-known upstream reg-
ulators of mTOR signaling.38 Previous findings from our labo-
ratory have shown that activation of AMPK by agents such as 
metformin could inhibit ovarian cancer cell growth by repress-
ing the mTOR signaling pathway.35 As expected, Western blot-
ting revealed that treatment of the ovarian cancer cell lines 
Figure 5. BME functions as a natural CaMKKβ/AMPK activator, repressing mTOR signaling activity in an AMP-independent manner. 
(A) Western blot analysis revealed that phosphorylation of Thr172 on AMPK increased in response to Chinese BME (1%, 2.5%, and 
5%, volume/volume [v/v]) in both WT and RG HEK-293 cells. Representative cropped blots are presented for the 2 groups. (B) As 
in (A) but showing a time course with 5% (v/v) BME. (C) A CaMKKβ inhibitor blocked BME-mediated Thr172 phosphorylation in 
WT and RG cells. Treatment with STO-609 (10 µM) blocked Thr172 phosphorylation induced by BME and A23187 (2 µm; 8 hours). 
Representative cropped blots are presented for the 2 groups. (D) Western blot analysis showing that the phosphorylation of mTOR 
and p70S6K was decreased in ovarian cancer cell lines—that is, A2780cp, C13*, and OV2008—treated with 1%, 5%, and 10%, v/v 
Chinese BME for 24 hours. Representative cropped blots are presented.
Abbreviations: BME, bitter melon extract; CaMKKβ, Ca2+/calmodulin-dependent protein kinase-β; AMPK, AMP-activated protein kinase; WT, wild-
type, AMP-sensitive AMPK-γ2; RG, AMP/ADP-insensitive R531G mutant AMPK-γ2.
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A2780cp, C13*, and OV2008 with 5% or 10% (v/v) Chinese 
BME for 24 hours yielded a marked reduction in phosphory-
lation of both mTOR (Ser2448) and its downstream target 
p70S6K (Ser371; Figure 5D). Collectively, these findings 
demonstrate that BME induces AMPK activation via the 
CaMKKβ pathway in an AMP-independent manner, whereas 
the activated AMPK then impairs cell growth and ovarian 
cancer cell metabolism, at least in part, via inhibition of 
mTOR signaling.
BME Also Suppresses the AKT/ERK/FOXM1 
Signaling Cascade
Our previous studies have shown that pharmacological 
AMPK activators such as A23187, AICAR, and metformin 
cause inhibition of human cervical cancer cell growth by 
repressing AKT/FOXO3a/FOXM1 signaling.19 Similarly, 
these AMPK activators, as well as hypoxia, not only acti-
vated AMPK but also inhibited expression of FOXM1 in 
ovarian cancer cells (Supplementary Figure S4, available at 
http://ict.sagepub.com/supplemental). To test whether BME 
could mediate similar effects in human ovarian cancer cell 
lines, A2780cp and C13* cells were treated with different 
concentrations and varieties of BME. After treatment with 
Chinese BME (1%, 5%, and 10%, v/v), the expression level 
of FOXM1 and phosphorylation of AKT (Ser473) and ERK 
decreased, whereas phosphorylation of AMPK at Thr172 
was concomitantly elevated (Figure 6A). Similar effects 
were observed in SKOV3 and OV2008 cells treated with 
Thailand BME (2.5% and 5%, v/v; Figure 6B) or Taiwanese 
BME (10%, v/v; Figure 6C). Additionally, qPCR analysis 
demonstrated that the mRNA expression level of FOXM1 in 
A2780cp, C13*, and OV2008 cells was markedly reduced 
after treatment with BME (5%, v/v) for 10 hours (Figure 
6D). To exclude off-target effects of AMPK activators, the 
AMPK inhibitor compound C was applied. After treatment 
with compound C (10 µM), the expression of p-AMPKα 
(Thr172) was significantly attenuated, whereas the expres-
sion of FOXM1 and phosphorylation of AKT (Ser473) and 
ERK were moderately increased in A2780cp cells as com-
pared with the control (Figure 6E). Thus, AMPK activation 
reduced the expression of FOXM1 at both the protein and 
mRNA levels via the AKT/ERK signaling cascade. To fur-
ther demonstrate that BME causes growth inhibition of 
ovarian cancer cells through activation of the AMPK sig-
naling pathway, the AMPK activity was specifically sup-
pressed by siRNA-mediated knockdown of AMPKα. As 
expected, knockdown of AMPKα1 (dominant isoform; 
Figure 6F) could significantly reduce the suppressive effect 
of Chinese BME (1%, v/v) on ovarian cancer cell growth 
(Figure 6G). It is important to note that the enhanced cancer 
cell growth mediated by cotreatment of Chinese BME (1%, 
v/v) and cisplatin (2 µg/mL) was remarkably reduced in 
AMPKα1 knockdown cells as compared with the scrambled 
control in a cisplatin-resistant cell line, A2780cp (Figure 
6G). Indeed, Western blot analysis confirmed that there was 
no reduction in the expression of FOXM1 and phosphoryla-
tion of AKT (Ser473) and ERK in A2780cp cells with 
AMPKα1 knockdown cells after treatment with 10% (v/v) 
Chinese BME for 24 hours, as compared with the vector 
control (Figure 6H). These findings support our notion that 
activation of AMPK by natural AMPK activator BME sup-
presses the cell growth of ovarian cancer through suppress-
ing the AKT/ERK/FOXM1 signaling cascade.
Discussion
Bitter melon has been utilized as a hypoglycemic and anti-
diabetic agent in Chinese and Indian Ayurvedic traditional 
medicine for hundreds of years.39 Emerging evidence has 
suggested that many other dietary phytochemicals, such as 
resveratrol and curcumin have anticancer effects by target-
ing cancer cell metabolism,29,40 and the antitumor activity 
of bitter melon has recently begun to attract attention.41 For 
instance, the crude extract from the fruits of bitter melon 
induced cell cycle arrest and promoted apoptosis in adre-
nocortical cancer cells NCI H295R42 and breast cancer 
cells MCF-7 and MDA-MB-231.29 Additionally, leaf 
BMEs had been documented to impede the proliferation of 
rat prostate cancer cells PLS10.43 These results suggest that 
BME not only has the ability to reduce cancer progression, 
but also has the potential to prevent ovarian cancer devel-
opment. In this study, we confirmed the capacity of BME 
to suppress proliferation, migration, and invasion of ovar-
ian cancer cells. Notably, BME showed no obvious toxicity 
in normal ovarian epithelial cells (HOSEs) or nude mice 
but enhanced the cytotoxicity of cisplatin in ovarian cancer 
cells, both in vitro and in vivo. It is important to note that 
our mechanistic studies are the first to show that BME dif-
fers from other xenobiotic AMPK activators, in that it acti-
vates AMPK in an AMP-independent manner through 
CaMKKβ signaling. Such BME-mediated AMPK activa-
tion significantly inhibits ovarian cancer cell growth by 
repressing both mTOR/P70S6K and AKT/ERK/FOXM1 
cascades.
We and others have previously reported that pharmaco-
logical AMPK activators such as metformin impair cell pro-
liferation of various human cancers.18,19,44 In this study, we 
demonstrated that BME functions as a natural AMPK acti-
vator and executes both cytostatic and cytotoxic effects on 
ovarian cancer cells while not being toxic in normal immor-
talized ovarian epithelial cells (HOSEs) or nude mice (data 
not shown). Similar to metformin, BME induces cell cycle 
arrest and promotes apoptosis in ovarian cancer cells, caus-
ing arrest at the G0/G1 phase and increasing the sub-G1 
population of apoptotic cells. Induction of apoptosis was 
also revealed by elevated expression of other apoptotic 
markers, such as cleavage of caspase 3 and PARP.
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Figure 6. BME acts as a natural AMPK activator to repress FOXM1 expression via impairment of the AKT/ERK/FOXM1 signaling cascade. 
(A) Western blot analysis showing that the phosphorylation of Thr172 on AMPK was increased, whereas the levels of FOXM1 and the 
phosphorylation of AKT and ERK were reduced in ovarian cancer cell lines—that is, A2780cp and C13*—treated with Chinese BME (1%, 5%, 
and 10%, volume/volume [v/v]) for 24 hours. Representative cropped blots processed in parallel are presented. (B) AMPK was activated after 
treatment of SKOV3 cells with Thai BME (2.5% and 5%, v/v). (C) Expression of FOXM1 was decreased significantly and phosphorylation of 
AKT and ERK was reduced after treatment of OV2008 cells with Taiwanese BME (10%, v/v). (D) qPCR analysis demonstrating that FOXM1 
mRNA level of A2780cp, C13*, and OV2008 cells was markedly reduced when treated with Chinese BME (5%, v/v) for 24 hours; 18S RNA 
was used as an internal control. (E) Suppression of AMPK activity relieves AMPK-mediated FOXM1 inhibition. Western blot analysis showing 
that AKT/ERK/FOXM1 signaling increased when A2780cp cells were treated by the AMPK inhibitor, compound C (10 µM), whereas the 
level of AKT/ERK/FOXM1 signaling decreased when A2780cp cells were treated with Chinese BME (10%, v/v). Representative cropped blots 
are presented for the 2 groups. (F) Depletion of the endogenous AMPKα1 (α1KD) by siRNA knockdown approach in ovarian cancer cell 
lines such as A2780cp and ES2; NC represents the scrambled control. (G) XTT cell proliferation assay demonstrated that the growth rate of 
A2780cp cells with AMPKα1 knockdown was not suppressed by the treatment of BME (1%, v/v) as compared with the scrambled control. 
Additionally, the growth inhibitory effect was more obvious in A2780cp scrambled control cotreated with Chinese BME (1%, v/v) and cisplatin 
(2 µg/mL), whereas there was no significant reduction of cell growth in AMPKα1 knockdown A2780cp cells when cotreated with the same 
condition. (H) Western blot analysis showing that AKT/ERK/FOXM1 signaling slightly increased when AMPKα1 knockdown A2780cp cells  
(α1 KD) were treated with/without Chinese BME (10%, v/v) for 24 hours, as compared with the scrambled control (NC).
Abbreviations: BME, bitter melon extract; AMPK, AMP-activated protein kinase; qPCR, reverse transcription polymerase chain reaction.
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Tumor metastasis and invasiveness are two very chal-
lenging issues for ovarian cancer patients. To address the 
functional role of BME in ovarian cancer metastasis, we 
examined its effect on ovarian cancer cell motility. Our find-
ings clearly demonstrate that BME markedly suppresses cell 
migration and the invasive properties of ovarian cancer cells, 
suggesting that BME may possess not only antitumor but 
also antimetastatic function in ovarian cancer.
The differing abilities among the varieties of BME in 
suppressing ovarian cancer cell tumorigenicity and chemo-
resistance are another interesting finding in this study. 
Kusamran et al32 have recently reported that Thai bitter 
melon contains more bioactive substances than the Chinese 
variety that inhibit some mono-oxygenases, displaying che-
mopreventive potential, indicating that the presence of anti-
tumorigenic substances in BME may vary among different 
varieties. Indeed, numerous reports have documented that 
bitter melon contains many bioactive substances, nutrients, 
and phytochemicals, such as crude protein, minerals, and 
flavonoids, in leaves from different varieties and at different 
stages of maturity.45 Hence, its ability to activate AMPK as 
well its antitumor activity may vary. Thus, cucurbitane-type 
triterpenoids,46 kuguaglycoside C,47 MAP30,41 and kugua-
cin J48 from bitter melon have all been shown to exhibit 
antitumor effects on various human cancer cells. It is impor-
tant to note that recent studies have documented that triter-
penoids (BMTs) such as BMT1 and BMT17 derived from 
BME possess the capacity for activation of AMPK.9,49 An 
aglycone form of cucurbitane triterpenoid, cucurbitacin E, 
has been reported to induce autophagy in human cancer 
cells through upregulating AMPK activity.50 Moreover, 
other triterpenoids such as momordicine I, momordicine II, 
kuguaglycoside G, and cucurbitacin I in bitter melon juice 
have also showed antitumorigenic effects on pancreatic car-
cinoma through activation of the AMPK pathway.51 These 
studies suggest that there are potential bioactive substances 
in BME used as AMPK activators in antitumor application.
Many conventional AMPK activators such as metfor-
min, berberine, resveratrol, and rosiglitazone are secondary 
plant metabolites or xenobiotics activating AMPK by sup-
pressing mitochondrial function and thus increasing cellular 
AMP to ADP and ADP to ATP ratios.52,53 In contrast, we are 
the first to demonstrate that BME activates AMPK in an 
AMP-independent manner because it triggered Thr172 
phosphorylation equally in HEK293 cells stably, overex-
pressing either WT cells or RG cells.52 Interestingly, fre-
quent mutations and deletions of LKB1 are found in human 
cancers,54-56 and our previous study demonstrated that loss 
of LKB1 reduced the efficacy of AMP- and LKB1-
dependent activators such as AICAR in inhibiting tumor cell 
growth.57 However, CaMKKβ provides an alternative pathway 
to activate AMPK in an LKB1-independent manner.58 Using 
the WT and RG HEK293 cells, we provide convincing evi-
dence that BME activates AMPK via CaMKKβ-dependent 
signaling only; this has not been reported thus far. Recent 
evidence has shown that CaMKKβ is highly expressed and 
maybe used as a promising target for human cancers.59-61 
This may provide an advantage, in that BME will activate 
AMPK and suppress the mTOR signaling cascade even in 
tumor cells lacking LKB1. Furthermore, CaMKKβ is 
known to be expressed in host cells important in ovarian 
cancer, such as adipocytes.62 Adipocytes in close proximity 
to ovarian cancer cells are thought to provide the latter with 
fatty acids, supporting the growth of the tumors.63,64 It is 
possible that BME also activates AMPK in adipocytes, 
which is known to inhibit lipolysis,65,66 and may, therefore, 
deprive the tumor cells of nutrients derived from these 
neighboring cells.
Accumulating evidence has shown that the upregulation 
of FOXM1 is involved in the development of various 
human cancers.67-71 It is known that the aberrant activation 
of AKT and the increased expression of FOXM1 are 
remarkably associated with chemoresistance of human can-
cers.72,73 Coincidently, we have recently reported that phar-
macological activators of AMPK are able to repress the cell 
growth of cervical cancer by targeting FOXM1 in an AKT/
FOXO3a/FOXM1 signaling cascade.19 In this study, BME 
has been shown to sensitize two cisplatin-resistant ovarian 
cancer cell lines, A2780cp and C13*, to cisplatin-induced 
cytotoxicity. In our previous study74 and the present one, we 
clearly demonstrated that the inhibitory effect of cisplatin 
resistance of ovarian cancer cells by BME is through the 
AKT/FOXM1 signaling cascade. Moreover, our results 
showed that activation of AMPK either by pharmacological 
activators, by hypoxic stress, or by BME all not only reduce 
mTOR expression but also FOXM1 expression by sup-
pressing the AKT/ERK signaling pathway, thereby impair-
ing growth and chemoresistance of ovarian cancer cells. It 
is hoped that this targeted therapy may be able to overcome 
the problem of chemoresistance in ovarian cancer.
Conclusion
Our findings suggest that BME not only functions as a 
potential AMPK activator to prevent ovarian cancer progres-
sion and metastasis but could also be used as a supplement 
to enhance the efficacy of cisplatin-based chemotherapy in 
ovarian carcinoma. It is important to note that BME acts 
through a mechanism different from that of other pharmaco-
logical activators of AMPK and appears to be nontoxic; it 
may thus avoid side effects such as the lactic acidosis exhib-
ited by AMPK activators that act by inhibiting mitochon-
drial function, such as metformin and phenformin.
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